Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24501242 | 0.94 | NR1H2 (0.53) | NR1H2NAMPTGPR119PKMMEN1 | |
| SCHEMBL22906686 | 0.92 | NR1H2 (0.51) | NR1H2NAMPTGPR119PKMMEN1 | |
| SCHEMBL15297794 | 0.89 | NR1H2 (0.54) | NR1H2NAMPTGPR119MEN1KMT2A | |
| SCHEMBL18623977 | 0.88 | NR1H2 (0.46) | NR1H2NAMPTGPR119PKMMEN1 | |
| SCHEMBL17087673 | 0.88 | NR1H2 (0.46) | NR1H2NAMPTGPR119PKMMEN1 | |
| SCHEMBL18604606 | 0.88 | NR1H2 (0.46) | NR1H2NAMPTGPR119PKMMEN1 | |
| SCHEMBL18604605 | 0.88 | NR1H2 (0.46) | NR1H2NAMPTGPR119PKMMEN1 | |
| SCHEMBL25757567 | 0.88 | NR1H2 (0.57) | NR1H2NAMPTGPR119MEN1KMT2A | |
| SCHEMBL25757571 | 0.87 | NR1H2 (0.42) | NR1H2NAMPTGPR119MEN1KMT2A | |
| SCHEMBL850478 | 0.85 | GPR119 (0.50) | NR1H2GPR119PKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | NR1H2 566/4885NAMPT 1873/4885GPR119 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.